RayKnowChina Research Map
Shortlist

Guangzhou Medical University

广州医科大学

GuangzhouUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
2.2%Leads about 1 in 46 of China's research papers on NPC ▲ from 1.7%

Led 52 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
1
Research papers it led
52
Trials it led
5
Share of China's trials
0.8%
Share of the world's papers
1.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseImaging & AI
Papers it led5
  1. Prognostic value of thrombocytosis in nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.2025BMC cancerFree full text
  2. Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis.2025European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  3. Prognostic value of tumour-stroma ratio in nasopharyngeal carcinoma: a two-center retrospective study.2025Radiation oncology (London, England)Free full text
  4. Control of dental calculus Prevents severe Radiation-Induced oral mucositis in patients undergoing radiotherapy for nasopharyngeal carcinoma.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  5. Prediction of immunotherapy response in nasopharyngeal carcinoma: a comparative study using MRI-based radiomics signature and programmed cell death ligand 1 expression score.2025European radiology
Trials on ClinicalTrials.gov6
  1. Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal CarcinomaRecruitingNCT04437329Lead sponsorPhase 3Start 2020-08
  2. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12
  3. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and ImmunotherapyRecruitingNCT07328841Study sitePhase 3Start 2025-11
  4. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  5. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaRecruitingNCT07328854Study sitePhase 3Start 2025-11
  6. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.4%Leads under 1 in 100 of China's research papers on ESCC

Led 11 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 0020242025: 222025
ThemesMolecular markers & genomicsNeoadjuvant & combined treatmentImmunotherapy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Fifth Affiliated Hospital of Guangzhou Medical University5
  2. First Affiliated Hospital of Guangzhou Medical University3
  3. Affiliated Panyu Central Hospital of Guangzhou Medical University1
  4. Affiliated Cancer Hospital of Guangzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.9%Leads under 1 in 100 of China's research papers on HCC

Led 125 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
18
Research papers it led
125
Trials it led
32
Share of China's trials
2.2%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 002025
ThemesImmunotherapy & targeted drugsRecurrence & prognosisImaging, AI & early detection

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Affiliated Hospital of Guangzhou Medical University39
  2. Affiliated Cancer Hospital of Guangzhou Medical University31
  3. Guangzhou Women and Children's Medical Center Counted in the group total13
  4. First Affiliated Hospital of Guangzhou Medical University Counted in the group total9
  5. Third Affiliated Hospital of Guangzhou Medical University Counted in the group total8
  6. Sixth Affiliated Hospital of Guangzhou Medical University Counted in the group total7

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC.2026Journal of hepatology
  2. Targeting cell-state plasticity driven by FOXM1/CEBPB axis disrupts developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma.2026Journal of hepatology
  3. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.2023Journal for immunotherapy of cancerFree full text
  4. Blockade of NMT1 enzymatic activity inhibits N-myristoylation of VILIP3 protein and suppresses liver cancer progression.2023Signal transduction and targeted therapyFree full text
  5. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.2021Cancer communications (London, England)Free full text
Trials on ClinicalTrials.gov6
  1. Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular CarcinomaNot yet recruitingNCT07657273Lead sponsorPhase 2Start 2026-06
  2. Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCCRecruitingNCT06904196Lead sponsorPhase 2Start 2025-04
  3. Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTTRecruitingNCT06904183Lead sponsorPhase 2Start 2025-04
  4. Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTTRecruitingNCT06492395Lead sponsorPhase 3Start 2024-08
  5. DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCCRecruitingNCT06397235Lead sponsorPhase 2Start 2024-05
  6. Y-90 SIRT for Unresectable HCC Larger Than 7cmRecruitingNCT06707233Lead sponsorPhase 2Start 2024-12

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.4%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 41 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
1
Research papers it led
41
Trials it led
4
Share of China's trials
0.3%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesPeritoneal spread & advanced diseaseImaging & AIImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Papers it led5
  1. Clinicopathological characterization of gastric amphicrine carcinoma: A case series.2026Annals of diagnostic pathology
  2. Multimodal radiopathomics signature for prediction of response to immunotherapy-based combination therapy in gastric cancer using interpretable machine learning.2025Cancer letters
  3. Intense 18 F-FAPI-04 Uptake in Bone Marrow Metastasis From Recurrent Postoperative Gastric Cancer Negative on 18 F-FDG PET/CT.2025Clinical nuclear medicine
  4. Prognostic value of diffusion-weighted imaging to cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for patients with gastric cancer and peritoneal metastases.2025BMC cancerFree full text
  5. An interpretable machine learning model based on computed tomography radiomics for predicting programmed death ligand 1 expression status in gastric cancer.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
Trials on ClinicalTrials.gov6
  1. Triplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsRecruitingNCT05187338Lead sponsorPhase 1/Phase 2Start 2021-11
  2. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  3. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  4. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  5. Prediction of Peritoneal Metastasis for Gastric Cancer Based on RadiomicsRecruitingNCT05722275Study siteStart 2023-01
  6. Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric CancerStatus unknownNCT03179579Lead sponsorPhase 3Start 2017-08

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
5.8%Leads about 1 in 17 of China's research papers on Hepatoblastoma

Led 9 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
2.0%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 222025

Hospitals counted here

  1. Guangzhou Women and Children's Medical Center9

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
1.0%Leads about 1 in 100 of China's research papers on Retinoblastoma ▼ from 1.8%

Led 3 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Guangzhou Women and Children's Medical Center3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.3%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 7 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 2220242025: 002025

Over half of these papers are lab or animal studies.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
3.1%Leads about 1 in 32 of China's research papers on Neuroblastoma ▼ from 5.2%

Led 35 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
1
Research papers it led
35
Trials it led
1
Share of China's trials
2.4%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.7%Leads under 1 in 100 of China's research papers on Myeloma ▼ from 1.4%

Led 12 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025
ThemesDrug combinationsRelapse & resistanceDiagnosis, MRD & risk

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Affiliated Hospital of Guangzhou Medical University5
  2. Fifth Affiliated Hospital of Guangzhou Medical University Counted in the group total2
  3. First Affiliated Hospital of Guangzhou Medical University Counted in the group total2
  4. Affiliated Cancer Hospital of Guangzhou Medical University2
  5. Affiliated Traditional Chinese Medicine Hospital of Guangzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
1.3%Leads about 1 in 75 of China's research papers on B-ALL ▼ from 2.0%

Led 3 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
1
Research papers it led
3
Trials it led
2
Share of China's trials
0.8%
Share of the world's papers
0.3%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025
ThemesMRD & relapseChildrenPhiladelphia chromosome & genetics

Hospitals counted here

  1. Guangzhou Women and Children's Medical Center2
  2. Affiliated Cancer Hospital of Guangzhou Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
0.5%Leads under 1 in 100 of China's research papers on HLH New since 2021

Led 2 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025
ThemesEBV & infection triggersChildren

Hospitals counted here

  1. First Affiliated Hospital of Guangzhou Medical University Counted in the group total1
  2. Second Affiliated Hospital of Guangzhou Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
8.6%Leads about 1 in 12 of China's research papers on Beta thalassaemia ▼ from 20.0%

Led 27 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
1
Research papers it led
27
Trials it led
1
Share of China's trials
2.1%
Share of the world's papers
1.6%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
0.0%Leads none of China's research papers on Haemophilia A

Led 0 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
3.1%Leads about 1 in 32 of China's research papers on Thrombotic thrombocytopenic purpura New since 2021

Led 2 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Sixth Affiliated Hospital of Guangzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
0.6%Leads under 1 in 100 of China's research papers on NMOSD ▼ from 2.1%

Led 3 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025
ThemesAntibodies & diagnosisBiologic drugsAcute attack treatment

Hospitals counted here

  1. Second Affiliated Hospital of Guangzhou Medical University2
  2. Eighth People's Hospital of Guangzhou Medical University1
  3. Guangzhou Women and Children's Medical Center1
  4. Affiliated Cancer Hospital of Guangzhou Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
1.0%Leads about 1 in 100 of China's research papers on Wilson disease

Led 2 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025
ThemesGenetics (ATP7B)Diagnosis & copper testsChildren

Hospitals counted here

  1. Guangzhou Women and Children's Medical Center2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Clinical characteristics and prognosis of early diagnosed Wilson's disease: A large cohort study.2024Liver international : official journal of the International Association for the Study of the Liver
  2. Assessment of the diagnostic value of serum ceruloplasmin for Wilson's disease in children.2022BMC gastroenterologyFree full text

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
9.3%Leads about 1 in 11 of China's research papers on Biliary atresia

Led 20 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
20
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
2.6%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 222025
ThemesScreening & diagnosisDisease mechanisms

Hospitals counted here

  1. Guangzhou Women and Children's Medical Center19

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Peripheral blood CD177+ cells as an early diagnostic marker for biliary atresia: A prospective multicentre study in pediatric patients with cholestasis.2022Journal of hepatology
  2. CD177+ cells produce neutrophil extracellular traps that promote biliary atresia.2022Journal of hepatology
  3. Identification of Biliary Atresia in Infantile Cholestasis: Integrating Radiomics With MRCP for Unobservable Extrahepatic Biliary Systems.2025Journal of computer assisted tomography
  4. Early differential diagnosis of cystic biliary atresia and choledochal cyst in the fetus: A multicenter retrospective study.2025Journal of hepato-biliary-pancreatic sciences
  5. Role of indocyanine green-guided near-infrared fluorescence imaging in identification of the cause of neonatal cholestasis.2024MedicineFree full text
Trials on ClinicalTrials.gov4
  1. Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomyTerminatedNCT06121375Study sitePhase 2/Phase 3Start 2024-09
  2. An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaActive, not recruitingNCT05426733Study sitePhase 3Start 2022-07
  3. Evaluation of Maralixibat in Biliary Atresia Response Post-KasaiCompletedNCT04524390Study sitePhase 2Start 2021-07
  4. Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)CompletedNCT04336722Study sitePhase 3Start 2020-07

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
1.5%Leads about 1 in 66 of China's research papers on Anti-NMDA receptor encephalitis ▲ from 0.8%

Led 4 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. Guangzhou Women and Children's Medical Center3
  2. Affiliated Brain Hospital of Guangzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
2.8%Leads about 1 in 35 of China's research papers on Idiopathic pulmonary fibrosis ▲ from 2.0%

Led 28 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
28
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 2220242025: 112025

Over half of these papers are lab or animal studies.

Papers it led5
  1. Characterizing the lavage and serum cytokine profiles of interstitial pneumonia with autoimmune features and their implications for progressive fibrosis.2024Rheumatology (Oxford, England)
  2. Overexpression of STX11 alleviates pulmonary fibrosis by inhibiting fibroblast activation via the PI3K/AKT/mTOR pathway.2024Signal transduction and targeted therapy
  3. Survival and early outcomes following lung transplantation for interstitial lung disease associated with non-scleroderma connective tissue disease: a national cohort study.2025Clinical and experimental rheumatology
  4. Detection of interstitial pneumonia with autoimmune features and idiopathic pulmonary fibrosis are enhanced by involvement of matrix metalloproteinases levels and clinical diagnosis.2022Journal of clinical laboratory analysis
  5. Outcomes after lung transplantation among Chinese patients with connective tissue disease-associated interstitial lung disease and pulmonary hypertension: a retrospective cohort study.2022Clinical and experimental rheumatology
Trials on ClinicalTrials.gov6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07121413Study sitePhase 2Start 2025-11
  3. A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07933133Study sitePhase 2Start 2026-12
  4. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  5. Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06230822Study sitePhase 1Start 2024-03
  6. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09

PubMed searchClinicalTrials.gov

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病
6.7%Leads about 1 in 15 of China's research papers on Lymphangioleiomyomatosis ▲ from 3.9%

Led 3 of 45 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.1%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

Hospitals counted here

  1. First Affiliated Hospital of Guangzhou Medical University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.4%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis

Led 3 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.05%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Affiliated Brain Hospital of Guangzhou Medical University2
  2. Third Affiliated Hospital of Guangzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
1.4%Leads about 1 in 71 of China's research papers on Duchenne muscular dystrophy ▼ from 4.1%

Led 3 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Guangzhou Women and Children's Medical Center2
  2. Third Affiliated Hospital of Guangzhou Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Alport syndrome

Alport 综合征
3.5%Leads about 1 in 29 of China's research papers on Alport syndrome New since 2021

Led 2 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Guangzhou Women and Children's Medical Center2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.0%Leads none of China's research papers on IgA nephropathy

Led 0 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%
Trials on ClinicalTrials.gov2
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.Status unknownNCT02160132Study sitePhase 2Start 2014-06

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
1.0%Leads about 1 in 99 of China's research papers on Osteogenesis imperfecta ▼ from 4.6%

Led 1 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Guangzhou Women and Children's Medical Center1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Congenital diaphragmatic hernia

先天性膈疝
18.3%Leads about 1 in 5 of China's research papers on Congenital diaphragmatic hernia ▲ from 12.9%

Led 11 of 60 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (18.3%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025

Hospitals counted here

  1. Guangzhou Women and Children's Medical Center11

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
5.6%Leads about 1 in 18 of China's research papers on Hirschsprung disease ▼ from 10.1%

Led 9 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.2%
Papers led per year
2021: 4420212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Guangzhou Women and Children's Medical Center7
  2. Children's Medical Center1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov